Nicotinamide Mononucleotide (NMN): Difference between revisions

Nicotinamide Mononucleotide (NMN) (view source)

301 bytes added , 14 December 2023

no edit summary

2,851

edits

@@ Line 81: / Line 81: @@
 === MIB-626 ===
-[[File:MIB-626 NAD+ .png|thumb|The placebo capsules had no effect on NAD+ levels over the course of 14 days (left graph). NMN doses of 1,000 mg taken once daily doubles NAD+ levels (middle graph). When taken twice daily, NMN triples NAD+ levels (right graph).{{pmid|35182418}}]]
+[[File:MIB-626 NAD+ .png|thumb|alt=Graphs showing the effect of NMN on NAD+ levels. The left graph indicates no change in NAD+ levels with placebo over 14 days. The middle graph shows a doubling of NAD+ levels with a daily dose of 1,000 mg NMN. The right graph demonstrates a tripling of NAD+ levels with a twice-daily dose of NMN.|The placebo capsules had no effect on NAD+ levels over the course of 14 days (left graph). NMN doses of 1,000 mg taken once daily doubles NAD+ levels (middle graph). When taken twice daily, NMN triples NAD+ levels (right graph).{{pmid|35182418}}]]
 MIB-626, developed by ''Metro International Biotech'', is a microcrystalline form of NMN. This formulation may offer enhanced stability, solubility, or bioavailability compared to the regular crystalline form of NMN, potentially optimizing the efficacy of NMN supplementation. MetroBiotech plans to bring MIB-626 on the market as drug, not as dietary supplement. For that reason, several clinical trials are ongoing evaluating the effects and safety of MIB-626 on humans.